2022-05-02
ViewReleaseInStandardHtml

Trading in NeoDynamics shares on Nasdaq First North starts today

Shares in the MedTech company NeoDynamics AB (publ) starts trading on Nasdaq First North Growth Market in Stockholm today.

“Trading on Nasdaq strengthens our credibility in the US market, where we intend to introduce our biopsy system NeoNavia and also look for partners”, says NeoDynamic's CEO Anna Eriksrud.

The listing ceremony can be watched on the following link: https://vimeo.com/event/1411317/6f4ff7bb35

Shareholders in NeoDynamics will not have to take any action in connection with the list change. The shares will trade under the same ticker, NEOD and ISIN code SE SE0011563410.

For further information, please contact:

CEO Anna Eriksrud, phone +46 708 444 966 or e-mail anna.eriksrud@neodynamics.com

CFO Aaron Wong, phone +46 73 597 2011 or e-mail aaron.wong@neodynamics.com

 

 

About NeoDynamics

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in breast and axilla in over 500 patients.

 

About NeoNavia

NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. It consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumour whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.